SAR-411298
- Generic Name
- SAR-411298
A Clinical Trial to Assess the Clinical Benefit of SSR411298 as Adjunctive Treatment for Persistent Cancer Pain
Phase 2
Terminated
- Conditions
- PainBreakthrough Cancer Pain
- Interventions
- Drug: Placebo (for SSR411298)
- First Posted Date
- 2011-09-23
- Last Posted Date
- 2013-03-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 5
- Registration Number
- NCT01439919
- Locations
- 🇺🇸
Investigational Site Number 840006, Flat Rock, North Carolina, United States
🇺🇸Investigational Site Number 840005, Canton, Ohio, United States
An Eight-week Study of SSR411298 as Treatment for Major Depressive Disorder in Elderly Patients
Phase 2
Completed
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2013-03-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 527
- Registration Number
- NCT00822744
- Locations
- 🇺🇦
Sanofi-Aventis Administrative Office, Kiev, Ukraine
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath